Journal Logo

E-39 Free Communication/Poster - Ergogenic Aids III - Bicarbonate and Caffeine Friday, June 1, 2018, 7: 30 AM - 12: 30 PM Room: CC-Hall B

Optimising Sodium Bicarbonate Supplementation

Are Gastro-resistant Capsules The Answer?

2401 Board #237 June 1 11

00 AM - 12

30 PM

Oliveira, Luana F.; Saunders, Bryan; Yamaguchi, Guilherme; Gualano, Bruno; Roschel, Hamilton; Artioli, Guilherme G.

Author Information
Medicine & Science in Sports & Exercise: May 2018 - Volume 50 - Issue 5S - p 595
doi: 10.1249/01.mss.0000537048.38961.04
  • Free

PURPOSE: To investigate the effects of sodium bicarbonate (SB) delivery method (gastro-resistance or gelatin capsules) and dosage on bicarbonate increase and side- effects incidence.

METHODS: Fourteen healthy men (age 27 ± 5 y; body mass [BM] 76.1 ± 11.4 kg; height 1.75 ± 0.06 m) participated in a double-blind and crossover study, composed of five laboratory visits. During each visit they received a different treatment: 0.3 g•kg-1 BM of SB in gastro-resistent (RES3) and gelatine capsules (GEL3); 0.1 g•kg-1 BM of SB in gastro-resistent (RES1) and gelatine capsules (GEL1); and 0.3 g•kg-1 BM of corn flour (PLA). Following an overnight fast, participants consumed a standardised breakfast one hour before ingesting the supplements. Blood samples were taken before and every 10-min following supplement ingestion for 3 h and then every 20 min for a further 1h and were analysed for bicarbonate concentration (RAPIDLab 348, Siemens). Area under the curve (AUC), and peak bicarbonate were recorded. Side- effects were assessed using a modified questionnaire. Data were analysed using mixed-model ANOVA for blood variables and Friedman test for side-effects.

RESULTS: There was a significant main effect of treatment on AUC and peak bicarbonate (both p < 0.001), with greater values in RES3 (AUC: 1594.5; peak: 36.4 mmol•L-1) and GEL3 (AUC: 1641.6; peak: 35.1 mmol•L-1) compared to RES1 (AUC: 1069.6; peak: 31.8 mmol•L-1), GEL1 (AUC: 888.7; peak: 31.5 mmol•L-1) and PLA (AUC: 849.3; peak: 29.7 mmol•L-1); there were no differences between types of capsules. Side-effects were significantly different between treatments (X2=13.545; p=0.009), with higher incidence in RES3 and GEL3 than RES1, GEL1 and PLA, with no differences between capsule types.

CONCLUSIONS: The current study showed thatblood variables were not different when SB was delivered in gastro-resistant and gelatine capsules, nor were any associated side-effects. The only differences shown were due to dose and not the type of capsule. SB supplementation in gastro-resistent capsules did not lead to greater increases in circulating bicarbonate or less side-side effects compared to gelatine capsules.

© 2018 American College of Sports Medicine